Ibogaine Treatment Shows Sustained Improvement in PTSD, Depression Among Veterans in Stanford Study

The study involved 30 male veterans, 23 of whom had PTSD, and focused on those with traumatic brain injuries. Participants received oral ibogaine along with magnesium infusions intended to mitigate heart-related risks, conducted at a clinic in Mexico. Researchers monitored participants at three, six, nine, and twelve months post-treatment, with 25 completing the follow-up year. Earlier results reported significant symptom improvements in the weeks following treatment.

One month after receiving ibogaine, participants experienced an 88% reduction in PTSD symptoms, an 87% decrease in depression, and an 81% drop in anxiety. By the one-year mark, veterans continued to show substantial reductions in these areas, along with a decrease in functional disability. Among those who achieved remission shortly after the treatment, estimates indicated an 84% probability of remaining in remission for PTSD, 66% for depression, and 61% for anxiety.

Camarin Rolle, a co-senior author and clinical assistant professor at Stanford, noted the importance of these persistent reductions. Co-first author Jennifer Lissemore expressed excitement over the potential for long-lasting relief from a single treatment.

Despite the encouraging results, it is essential to note that the study lacked a control group and was open-label, meaning participants were aware of the treatment they received. This raises questions about whether the reported benefits were solely due to ibogaine or influenced by concurrent therapies, as some veterans also engaged in counseling or other psychedelic treatments after the initial intervention.

Funding for the research came from private donors and various foundations, and several study authors have connections to Stanford-owned intellectual property related to ibogaine treatment, which could present a conflict of interest. Ibogaine is classified as a Schedule I drug in the United States and is not approved by the FDA; it carries risks, particularly concerning heart health.

Given the legal restrictions on ibogaine in the U.S., individuals seeking treatment often travel abroad, as the participants did for this study. Treatment protocols outside of clinical settings may lack proper monitoring and screening, which is crucial for safety when using such a drug.

Those considering ibogaine as a treatment option should consult a healthcare professional to evaluate their heart health and medication regimen. Established PTSD treatments are available through the VA, and veterans in crisis can obtain immediate support by contacting the Veterans Crisis Line at 988 and pressing 1.

Furthermore, Texas has approved $50 million for clinical trials involving ibogaine, with plans for further studies in collaboration with university medical institutions. Recently, an executive order was signed to expedite federal reviews of psychedelic drugs, including ibogaine, underscoring a growing interest in the therapeutic potential of such substances.